The immunomodulatory effects of measles-mumps-rubella vaccination on persistence of heterologous vaccine responses
Corresponding Author
Petra Zimmermann
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia
Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
Department of Paediatrics, Fribourg Hospital HFR and Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Correspondence
Petra Zimmermann, Department of Paediatrics, The University of Melbourne, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.
E-mail: [email protected]
Search for more papers by this authorKirsten P Perrett
Population Allergy Research Group and Melbourne Children's Trial Centre, Murdoch Children's Research Institute, Parkville, VIC, Australia
Departments of Allergy and Immunology and General Medicine, Royal Children's Hospital Melbourne, Parkville, VIC, Australia
School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorFiona RM van der Klis
National Institute of Public Health and the Environment, Centre for Infectious Diseases, Bilthoven, The Netherlands
Search for more papers by this authorNigel Curtis
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia
Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
Search for more papers by this authorCorresponding Author
Petra Zimmermann
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia
Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
Department of Paediatrics, Fribourg Hospital HFR and Faculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland
Correspondence
Petra Zimmermann, Department of Paediatrics, The University of Melbourne, Royal Children's Hospital Melbourne, Parkville, VIC 3052, Australia.
E-mail: [email protected]
Search for more papers by this authorKirsten P Perrett
Population Allergy Research Group and Melbourne Children's Trial Centre, Murdoch Children's Research Institute, Parkville, VIC, Australia
Departments of Allergy and Immunology and General Medicine, Royal Children's Hospital Melbourne, Parkville, VIC, Australia
School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia
Search for more papers by this authorFiona RM van der Klis
National Institute of Public Health and the Environment, Centre for Infectious Diseases, Bilthoven, The Netherlands
Search for more papers by this authorNigel Curtis
Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia
Infectious Diseases Unit, The Royal Children's Hospital Melbourne, Parkville, VIC, Australia
Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC, Australia
Search for more papers by this authorAbstract
It is proposed that measles-containing vaccines have immunomodulatory effects which include a reduction in all-cause childhood mortality. The antibody response to heterologous vaccines provides a means to explore these immunomodulatory effects. This is the first study to investigate the influence of measles-mumps-rubella (MMR) vaccine on the persistence of antibodies to a broad range of heterologous infant vaccinations given in the first year of life. In total, 319 children were included in the study. All infants received routine vaccinations at 6 weeks, 4 and 6 months of age. At 12 months of age, 212 children were vaccinated with MMR and Haemophilus influenzae type b-meningococcus C (Hib-MenC) vaccines while the remaining 99 children had not yet received these vaccines. In the MMR/Hib-MenC-vaccinated group, blood was taken 28 ± 14 days after receiving these vaccines. Antibodies against diphtheria, tetanus, pertussis [pertussis toxin (PT), filamentous hemagglutinin, pertactin], poliomyelitis (type 1, 2, 3) and 13 pneumococcal serotypes were measured. Seroprotection rates and geometric mean antibody concentrations were compared between MMR/MenC-Hib-vaccinated and MMR/MenC-Hib-naïve participants. In the final analysis, 311 children were included. Seroprotection rates were lower in MMR/Hib-MenC-vaccinated children against PT and pneumococcal serotype 19A. After adjustment for prespecified factors, MMR/Hib-MenC-vaccinated infants had significantly higher antibody concentrations against tetanus (likely explained by a boosting effect of the carrier protein, a tetanus toxoid), while for the other vaccine antigens there was no difference in antibody concentrations between the two groups. MMR vaccination given at 12 months of age in a developed country does not significantly influence antibody concentrations to heterologous vaccines received in the first year of life.
Video Short
The immunomodulatory effects of measles‐mumps‐rubella vaccination on persistence of heterologous vaccine responses
by Zimmermann et al.Conflict of interest
The authors declare no conflict of interest.
References
- 1Higgins JP, Soares-Weiser K, Lopez-Lopez JA, et al. Association of BCG, DTP, and measles containing vaccines with childhood mortality: systematic review. BMJ 2016; 355: i5170.
- 2Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child 2017; 102: 1077–1081.
- 3Goodridge HS, Ahmed SS, Curtis N, et al. Harnessing the beneficial heterologous effects of vaccination. Nat Rev Immunol 2016; 16: 392–400.
- 4Saadatian-Elahi M, Aaby P, Shann F, et al. Heterologous vaccine effects. Vaccine 2016; 34: 3923–3930.
- 5Clemens JD, Stanton BF, Chakraborty J, et al. Measles vaccination and childhood mortality in rural Bangladesh. Am J Epidemiol 1988; 128: 1330–1339.
- 6Hansen JS, Thysen SM, Rodrigues A, et al. Is early measles vaccination associated with stronger survival benefits than later measles vaccination? BMC Public Health 2018; 18: 984.
- 7Aaby P, Martins CL, Ravn H, et al. Is early measles vaccination better than later measles vaccination? Trans R Soc Trop Med Hyg 2015; 109: 16–28.
- 8Hennino A, Cornu C, Rozieres A, et al. Influence of measles vaccination on the progression of atopic dermatitis in infants. Pediatr Allergy Immunol 2007; 18: 385–390.
- 9Nofal A, Nofal E, Yosef A, et al. Treatment of recalcitrant warts with intralesional measles, mumps, and rubella vaccine: a promising approach. Int J Dermatol 2015; 54: 667–671.
- 10Awal G, Kaur S. Therapeutic outcome of intralesional immunotherapy in cutaneous warts using the mumps, measles, and rubella vaccine: a randomized, placebo-controlled trial. J Clin Aesthet Dermatol 2018; 11: 15–20.
- 11Griffin DE. Measles vaccine. Viral Immunol 2018; 31: 86–95.
- 12Haralambieva IH, Kennedy RB, Ovsyannikova IG, et al. Variability in humoral immunity to measles vaccine: new developments. Trends Mol Med 2015; 21: 789–801.
- 13Samb B, Whittle H, Aaby P, et al. No evidence of long-term immunosuppression after high-titer Edmonstron-Zagreb measles vaccination in Senegal. J Infect Dis 1995; 171: 506–508.
- 14Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29: 6327–6334.
- 15Nolan T, Bernstein DI, Block SL, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008; 121: 508–516.
- 16Aaby P, Bukh J, Lisse IM, et al. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect 1984; 8: 13–21.
- 17Mina MJ, Metcalf CJ, de Swart RL, et al. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348: 694–699.
- 18de Vries RD, McQuaid S, van Amerongen G, et al. Measles immune suppression: lessons from the macaque model. PLoS Pathog 2012; 8: e1002885.
- 19de Swart RL, Ludlow M, de Witte L, et al. Predominant infection of CD150 + lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog 2007; 3: e178.
- 20Zamanian A, Mobasher P, Jazi GA. Efficacy of intralesional injection of mumps-measles-rubella vaccine in patients with wart. Adv Biomed Res 2014; 3: 107.
- 21Ota MO, Vekemans J, Schlegel-Haueter SE, et al. Influence of Mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168: 919–925.
- 22Freyne B, Donath S, Germano S, et al. Neonatal BCG vaccination influences cytokine responses to toll-like receptor ligands and heterologous antigens. J Infect Dis 2018; 217: 1798–1808.
- 23Kandasamy R, Voysey M, McQuaid F, et al. Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ 2016; 355: i5225.
- 24Kleinnijenhuis J, Quintin J, Preijers F, et al. Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014; 6: 152–158.
- 25Kleinnijenhuis J, van Crevel R, Netea MG. Trained immunity: consequences for the heterologous effects of BCG vaccination. Trans R Soc Trop Med Hyg 2015; 109: 29–35.
- 26Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012; 109: 17537–17542.
- 27Curtsinger JM, Valenzuela JO, Agarwal P, et al. Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol 2005; 174: 4465–4469.
- 28Gans HA, Maldonado Y, Yasukawa LL, et al. IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol 1999; 162: 5569–5575.
- 29Ovsyannikova IG, Reid KC, Jacobson RM, et al. Cytokine production patterns and antibody response to measles vaccine. Vaccine 2003; 21: 3946–3953.
- 30Rager-Zisman B, Bazarsky E, Skibin A, et al. The effect of measles-mumps-rubella (MMR) immunization on the immune responses of previously immunized primary school children. Vaccine 2003; 21: 2580–2588.
- 31Pabst HF, Spady DW, Carson MM, et al. Kinetics of immunologic responses after primary MMR vaccination. Vaccine 1997; 15: 10–14.
- 32Mina MJ. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. J Infect 2017; 74(Suppl 1): S10–S17.
- 33Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J Infect Dis 1996; 173: 1320–1326.
- 34Zimmermann P, Perrett K, Messina N, et al. The influence of neonatal Bacille Calmette-Guérin (BCG) immunisation on heterologous vaccine responses in infants in a randomised controlled trial. Vaccine 2019. in press
- 35Zimmermann P, Curtis N. The influence of BCG on vaccine responses—a systematic review. Expert Rev Vaccines 2018; 17: 547–554.
- 36Mullooly J, Black S. Simultaneous administration of varicella vaccine and other recommended childhood vaccines–United States, 1995–1999. MMWR Morb Mortal Wkly Rep 2001; 50: 1058–1061.
- 37Gans HA, Arvin AM, Galinus J, et al. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280: 527–532.
- 38Gans H, Yasukawa L, Rinki M, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 2001; 184: 817–826.
- 39Njie-Jobe J, Nyamweya S, Miles DJ, et al. Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years. Vaccine 2012; 30: 2543–2550.
- 40Lochlainn LN, de Gier B, van der Maas N, et al. Measles Vaccination Below 9 Months of Age: Systematic Literature Review and Meta-Analyses of Effects and Safety. Bildthoven, The Netherlands: Centre for Infectious Disease Control, National Institute for Public Health an the Environment (RIVM); 2015.
- 41Nair N, Gans H, Lew-Yasukawa L, et al. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007; 196: 1339–1345.
- 42van Gageldonk PG, van Schaijk FG, van der Klis FR, et al. Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus. J Immunol Methods 2008; 335: 79–89.
- 43de Voer RM, Schepp RM, Versteegh FG, et al. Simultaneous detection of Haemophilus influenzae type b polysaccharide-specific antibodies and Neisseria meningitidis serogroup A, C, Y, and W-135 polysaccharide-specific antibodies in a fluorescent-bead-based multiplex immunoassay. Clin Vaccine Immunol 2009; 16: 433–436.
- 44Elberse KE, Tcherniaeva I, Berbers GA, et al. Optimization and application of a multiplex bead-based assay to quantify serotype-specific IgG against Streptococcus pneumoniae polysaccharides: response to the booster vaccine after immunization with the pneumococcal 7-valent conjugate vaccine. Clin Vaccine Immunol 2010; 17: 674–682.
- 45Schepp RM, Berbers GA, Ferreira JA, et al. A novel multiplex poliovirus binding inhibition assay applicable for large serosurveillance and vaccine studies, without the use of live poliovirus. J Virol Methods 2017; 241: 15–23.
- 46de Voer RM, van der Klis FR, Engels CW, et al. Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides. Clin Vaccine Immunol 2008; 15: 1188–1193.
- 47Smits GP, van Gageldonk PG, Schouls LM, et al. Development of a bead-based multiplex immunoassay for simultaneous quantitative detection of IgG serum antibodies against measles, mumps, rubella, and varicella-zoster virus. Clin Vaccine Immunol 2012; 19: 396–400.
- 48Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17: 1055–1065.
- 49Freidl GS, Tostmann A, Curvers M, et al. Immunity against measles, mumps, rubella, varicella, diphtheria, tetanus, polio, hepatitis A and hepatitis B among adult asylum seekers in the Netherlands, 2016. Vaccine 2018; 36: 1664–1672.
Citing Literature
Journal of the Australian and New Zealand Society for Immunology
